Abstract
Purpose. The concept of Hydrophilic Sphere Stabilization, or Hydrophobic Shielding, has been postulated in the synthesis of biocompatible contrast agents in vascular imaging. To improve the safety of these polyiodinated agents, interactions with protein hydrophobic sites in biomacromolecules should be kept as low as possible. In order to evaluate the level of interactions with proteins, we have selected the serine proteinase Elastase, in presence of Iobitridol (Xenetix®), as a model.
Methods. The complex between Iobitridol and Pancreatic Porcine Elastase was investigated by X-ray diffraction techniques, on saturated monocrystals, using the synchrotron radiation at 0.98Å.
Results. In contrast to Iohexol, which displays several interactions including one in the active site, Iobitridol is unable to interact directly with elastase. Only one partially occupied site is found in between two molecules of the crystal packing.
Conclusions. The validation of the 'hydrophobic shielding' concept, which was at the origin of the design of the Iobitridol molecule, has been proven to be an essential feature in minimizing in vivo protein interactions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
R. Eloy, C. Corot, and J. Belleville. J Clin. Mat. 7:89–197 (1991).
P. M. Kopko, D. C. Smith, and B. S. Bull. Radiology 174:459–461 (1990).
E. F. Meyer Jr., G. M. Cole, R. Radhakrishnan, and O. Epp. Acta Cryst. B44:26–38 (1988).
T. Prangé, F. Gaudey, J. Ohanessian, D. Avenel, A. Neuman, C. Corot, and D. Meyer. FEBS Lett. 357:247–250 (1995).
I. Li de la Sierra, E. Papamichael, C. Sakarellos, J. L. Dimicoli, and T. Prangé. J. Molecular Recognition 3:36–44 (1990).
A. G. W. Leslie. 26th Joint CCP4 and ESF-EACMB Newsletter on Protein Crystallography. Warrington: SERC Daresbury Laboratory, U.K., 1992.
CCP4 Collaborative Computational Project, Number 4. Acta Cryst. D50:760–763 (1994).
F. C. Bernstein, T. F. Koetzle, J. B. Williams, E. F. Meyer Jr., M. D. Brice, J. R. Rodgers, O. Kennard, T. Shimanouchi, and M. Tasumi. J. Mol. Biol. 112:535–542 (1977).
W. A. Hendrickson and J. H. Konnert. Methods of Enzymol. 155:252–270 (1985).
F. Ganazzoli, A. Albinati, and D. Pitré. Acta Chim. Scand. 49:433–440 (1995).
D. Meyer, M. L. Fouchet, M. Petta, P. A. Carrupt, P. Gaillard, and B. Testa. Pharm. Res. 12:1583–1591 (1995).
M. L. Connoly. J. Appl. Cryst. 16:548–558 (1983).
S. J. Hubbard, K. H. Gross, and P. Argos. Protein Eng. 7:613–626 (1994).
L. Zhang and J. Hermans. Proteins 24:433–438 (1996).
M. H. Klapper. Biochim. Biophys. Acta. 229:557–566 (1971).
T. Prangé, L. Pernot, N. Colloc'h, S. Longhi, W. Bourquet, R. Fourme, and M. Schiltz. Protein Struct. and Funct. (in press).
B. P. Schoenborn. Nature (London) 214:1120–1122 (1967); R. F. Tilton and G. A. Petsko. Biochemistry 27:6574–6582 (1988).
G. Otting, E. Liepinsh, B. Halle, and U. Frey. Nature Struct. Biol. 4:396–404 (1997).
A. Morton and B. W. Matthews. Biochemistry 34:8576–8588 (1995).
A. C. Nunes and B. P. Schoenborn. Mol. Pharmacol. 9:835–839 (1973).
V. A. Feher, E. P. Baldwin, and F. W. Dahlquist. Nature Struct. Biol., 3:516–521 (1996).
R. F. Tilton, I. D. Kuntz, and G. A. Petsko. Biochemistry, 23:2849–2857 (1984).
W. Sachsenheimer, E. F. Pai, G. E. Schultz, and R. H. Schirmer. FEBS Lett., 79:310–312 (1977).
W. Settle. Function of the myoglobin molecule as influenced by anesthetic molecules. Guide to Molecular Pharmacology-Toxicology. (ed. R. M. Featherstone). M. Dekker and Co, New York, 1973.
K. W. Miller. Int. Rev. Neurobiol. 27:1–61 (1985).
N. P. Franks and W. R. Lieb. Nature (London) 367:607–614 (1994).
B. P. Schoenborn and R. M. Featherstone. Adv. Pharmacol. 5:1–17 (1967).
A. Volbeda, M. H. Charon, C. Piras, C. Hatchikian, M. Frey, and J. Fontecilla-Camps. Nature (London). 373:580–587 (1995).
V. N. Malashkevich, R. A. Kammerer, V. Efimov, T. Schulthess, and J. Engel. Science 274:761–765 (1996).
X. M. He and D. C. Carter. Nature (London) 358:209–215 (1992).
C. Corot and V. Sabattier. Action de l'Eastase sur un substrat synthétique, le N Succ(Ala)3pNA en presence de monomères iodés non ioniques. Report IHB VS 93-02, Biomatech, Châsse sur Rhône, France, 1993.
M. Schiltz, R. Fourme, I. Broutin, and T. Prangé. Structure, 3:309–316 (1995).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prangé, T., Neuman, A., Corot, C. et al. Study of the Complex Between the Contrast Agent lobitridol (Xenetix®) and Elastase (PPE): A Model for Hydrophobic Site Protection in Drug-Protein Interactions. Pharm Res 14, 1713–1717 (1997). https://doi.org/10.1023/A:1012123628123
Issue Date:
DOI: https://doi.org/10.1023/A:1012123628123